Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Completed · Phase 1

Conditions studied: Cancer, Graft-Versus-Host Disease

In brief

A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.

Key facts

Study ID

NCT00806728

Run by

MedImmune LLC

People needed

17

Starts

1998-05-01

Expected to finish

1998-12-01

Last updated by the study team

2008-12-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Allogeneic bone marrow or hematopoietic stem cell graft recipients
• Acute GVHD of at least grade II severity
• Failure of GVHD to improve on at least 2 mg/kg/day of methylprednisolone or prednisone for at least three days or recurrence of acute GVHD as corticosteroids are tapered from initial treatment of the initial episode of GVHD
• Evidence of engraftment (ANC over 1000 cells/mm3)
• Histologic evidence of GVHD from biopsy performed during the current episode
• Received GVHD prophylaxis of methotrexate, tacrolimus or cyclosporine
• Age at least 18 years
• Body weight under 130 kg
• Both males and females are eligible but females of childbearing potential will use an accepted method of avoiding pregnancy for at least 60 days after the end of treatment (which includes oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or a sterile sexual partner)

You may not qualify if…

• Previous receipt of MEDI-507
• Clinical or histologic manifestation of chronic GVHD
• Previous treatment with any anti-T-cell antibodies such as OKT®3 or daclizumab (Zenapax®)
• Receipt of antithymocyte globulin (ATGAM® or other ATG) since the day of transplant
• More than one allogeneic bone marrow or hematopoietic stem cell allograft
• Moribund and unlikely (in the opinion of the investigator) to survive 15 days
• Use of other investigational agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert)
• Any of the following clinical settings or diagnoses:
• Ø documented or presumed significant active infection Ø pregnancy or nursing mother Ø evidence of infection with HIV-1, hepatitis B or C virus Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator
• Histologically confirmed veno-occlusive disease of the liver
• Ascites on physical examination (this does not include small amounts of ascitic fluid detected only on ultrasound)

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• University of Colorado Health Sciences Center — Denver, Colorado, United States
• University of Michigan Hospital — Ann Arbor, Michigan, United States
• Washington University Medical Center — St Louis, Missouri, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• University Hospital-University of Oklahoma — Oklahoma City, Oklahoma, United States
• Western Pennsylvania Hospital - Western Pennsylvania Cancer Center — Pittsburgh, Pennsylvania, United States
• Baylor University Medical Center — Dallas, Texas, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States
• South Texas Cancer Institute at Methodist Hospital — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.